Top View
- FDA Briefing Document
- Horizon Scanning Status Report December 2020
- UNIVERSITY of CALIFORNIA Los Angeles Disease
- Measured Moments
- The State of Research in Dmd
- IPTR & PACS List: Non-Oncology
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Translarna™ (Ataluren) Is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
- Horizon Scanning Status Report June 2020 Prepared For: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036
- Rxoutlook® 3Rd Quarter 2020
- PRAC Draft Agenda of Meeting 11-14 February 2019
- High Potential Disruption Report May 2020
- Duchenne Muscular Dystrophy Well‑Established Corticosteroid Therapy Prolongs Life, and Potentially Curative New Treatments Are in Development
- Succinic Semialdehyde Dehydrogenase Deficiency
- Effectiveness of Pharmacological Treatments In
- Pediatric Year in Review
- Annual Report 2013
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Fourth Quarter and Full Year 2019 Financial Results & Corporate Update
- Current Translational Research and Murine Models for Duchenne Muscular Dystrophy
- An Analysis of Differential Acceptance Rates of Advisory Committee Recommendations By
- Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
- Overview of Gene Therapy in Spinal Muscular Atrophy and Duchenne
- 1 Basil Darras, MD (Chief of the Division of Clinical Neurology
- Fresh from the Biotech Pipeline—2016
- Brand Pipeline Forecast 4Th Quarter 2019
- Exondys, Through the Centralised Procedure Falling Within the Article 3(1) and Point 4 of Annex of Regulation (EC) No 726/2004
- A View Into Upcoming Specialty & Traditional Drugs
- Therapeutic Strategies for Duchenne Muscular Dystrophy: an Update
- Therapeutic Class Overview Duchenne Muscular Dystrophy (DMD) Agents
- Therapeutic Update on Neuromuscular Disorders SMA and DMD Conference Highlights from 2018 Disclaimer
- Risdiplam for Treating Spinal Muscular Atrophy in Children and Adults [ID1631]
- Human Metabolism Lecture Notes
- Translarna, INN-Ataluren
- 2020 Medicines in Development for Children
- A New Era in the Management of Neuromuscular Disorders in Children and Adolescents
- Pipeline Highlights 2016: Focus on Duchenne Muscular Dystrophy
- RNA-Targeted Therapies and High-Throughput Screening Methods
- Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
- Tenofovir Alafenamide
- 1 Glycans and Glycoproteins As Biomarkers and Treatments For
- Emerging Drugs for Duchenne Muscular Dystrophy
- Contents Academic Partnerships to Support Clinical Development
- Fda's Rocket Docket
- Methodik Der ATC-Klassifikation Und DDD-Festlegung Für Den Deutschen
- Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016